Evidence map›Paper›PMID 41314393›Full record

ReviewTransplantation and cellular therapy2026

Genetic Findings of Potential Donor Origin in Cells Used for Cell and Gene Therapy: Recommendations from the World Marrow Donor Association.

Angharad Pryce, Meghann Cody, Abeer Madbouly, Eefke van Eerden, Laura L Machin, Heather E Stefanski, Darren Hatton, Chloe Anthias, Diana Hernandez, Sarah Bannon and 2 more

Abstract readReview
In one paragraph

Review in Transplantation and cellular therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Angharad PryceAnthony Nolan, London, United Kingdom.
Meghann CodyCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.
Abeer MadboulyCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.
Eefke van EerdenWorld Marrow Donor Association, Leiden, The Netherlands.
Laura L MachinLancaster University, Lancaster, United Kingdom.
Heather E StefanskiCenter for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, Minnesota.
Darren HattonAnthony Nolan, London, United Kingdom.
Chloe AnthiasAnthony Nolan, London, United Kingdom.
Diana HernandezAnthony Nolan, London, United Kingdom.
Sarah BannonNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
Thilo MenglingDKMS Group, Tubingen, Germany.
David S AllanStem Cells, Canadian Blood Services, Ottawa, Ontario, Canada. Electronic address: David.allan@blood.ca.

Funding

Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

Manufacturing cell and gene therapy (CGT) products derived from donor cells may involve genetic and other testing that identifies unexpected findings of potential donor origin. Testing may be done to assess the safety of the product or manufacturing process and to assess gene transduction efficiency or aspects of cell expansion, and also may be performed in recipients of CGT products following infusion to monitor the effects of treatment. Tests that may identify unexpected findings in donor cells include chromosomal karyotyping, targeted tests for specific gene mutations or rearrangements, and large gene panels or whole genome sequencing to detect mutations or cytogenetic abnormalities of relevance to donors. Deciphering whether variants are of donor origin as opposed to introduced via manufacturing processes is key, as is having a framework for protecting donors that includes procedures for ensuring robust donor consent and appropriate pathways for disclosure of clinically relevant and actionable results. Building on recent recommendations from the World Marrow Donor Association regarding unexpected findings of potential donor origin following allogeneic hematopoietic cell transplantation, an expert group was assembled to review available evidence and develop a framework to apply to healthy volunteer donors who provide cells for the manufacturing of allogeneic CGT products. These guidelines aim to provide recommendations for predonation consenting, as well as a framework for informing and managing the care of donors when findings of potential donor origin are identified. Since many cellular therapies remain under development, donors who provide cells for any aspect of research and development of CGT products require special consideration. Realizing that cellular therapy may involve commercial entities and donors that are recruited within conventional stem cell registries or through other mechanisms, we provide suggestions on how recommendations can be adapted.

Indexed as

Cell- and Tissue-Based TherapyGenetic TherapyHematopoietic Stem Cell TransplantationTissue DonorsHumansCell and gene therapyEthicsGenetic findingsStem cell donorTransplantation

Identifiers

PMID41314393
PMCPMC12690604

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.